Exagen Inc. will announce Q3 2025 financial results on November 4, followed by a conference call with executives.
Quiver AI Summary
Exagen Inc., a provider of autoimmune testing, will announce its financial results for the third quarter of 2025 on November 4, 2025, prior to the market opening. The company's President and CEO, John Aballi, along with CFO Jeff Black, will discuss the results in a conference call at 8:30 a.m. ET. Interested parties can access the call via a U.S. dial-in number or an international number, and a webcast will also be available on Exagen's investor relations website. A replay of the call will be accessible until November 18, 2025. Based in Carlsbad, California, Exagen focuses on innovative autoimmune diagnostics aimed at improving patient care, with notable products such as AVISE® CTD, which aids in the early and accurate diagnosis of various autoimmune diseases.
Potential Positives
- Exagen Inc. is set to release its financial results for the quarter ended September 30, 2025, indicating transparency and accountability to its shareholders.
- The conference call hosted by the CEO and CFO will provide investors with insights into the company’s performance and future outlook.
- Exagen is highlighted as a leading provider of autoimmune diagnostics, reinforcing its position in a growing market focused on complex autoimmune conditions.
- The company emphasizes its commitment to innovation and improving clinical outcomes, which can enhance its reputation and attract investors interested in healthcare advancements.
Potential Negatives
- None
FAQ
When will Exagen release its financial results?
Exagen will release its financial results for the quarter ended September 30, 2025, on November 4, 2025.
What time is the Exagen conference call?
The conference call will be held at 8:30 a.m. ET (5:30 a.m. PT) on November 4, 2025.
How can I access the Exagen conference call?
You can access the conference call by dialing U.S. 201-389-0918 or International 877-407-0890.
Where can I find the Exagen webcast?
The webcast will be available on Exagen's investor relations website at investors.exagen.com.
What is Exagen's flagship product?
Exagen’s flagship product is AVISE® CTD, used for diagnosing complex autoimmune conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XGN Insider Trading Activity
$XGN insiders have traded $XGN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $XGN stock by insiders over the last 6 months:
- JOHN ABALLI (President and CEO) sold 31,787 shares for an estimated $375,598
- JEFFREY G. BLACK (Chief Financial Officer) sold 20,466 shares for an estimated $200,362
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XGN Hedge Fund Activity
We have seen 38 institutional investors add shares of $XGN stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. added 718,782 shares (+inf%) to their portfolio in Q2 2025, for an estimated $5,017,098
- WEXFORD CAPITAL LP added 416,348 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,906,109
- UBS GROUP AG added 383,691 shares (+613.7%) to their portfolio in Q2 2025, for an estimated $2,678,163
- RUSSELL INVESTMENTS GROUP, LTD. added 220,616 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,539,899
- FOURWORLD CAPITAL MANAGEMENT LLC added 208,527 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,455,518
- PERKINS CAPITAL MANAGEMENT INC removed 191,113 shares (-45.2%) from their portfolio in Q2 2025, for an estimated $1,333,968
- VANGUARD GROUP INC added 190,675 shares (+38.8%) to their portfolio in Q2 2025, for an estimated $1,330,911
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XGN Analyst Ratings
Wall Street analysts have issued reports on $XGN in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Keybanc issued a "Overweight" rating on 10/14/2025
- B. Riley Securities issued a "Buy" rating on 09/11/2025
- Canaccord Genuity issued a "Buy" rating on 07/30/2025
- Craig-Hallum issued a "Buy" rating on 07/23/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/15/2025
To track analyst ratings and price targets for $XGN, check out Quiver Quantitative's $XGN forecast page.
$XGN Price Targets
Multiple analysts have issued price targets for $XGN recently. We have seen 5 analysts offer price targets for $XGN in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Paul Knight from Keybanc set a target price of $15.0 on 10/14/2025
- Anderson Schock from B. Riley Securities set a target price of $15.0 on 09/11/2025
- Kyle Mikson from Canaccord Genuity set a target price of $11.0 on 07/30/2025
- John Wilkin from Craig-Hallum set a target price of $12.0 on 07/23/2025
- Ross Osborn from Cantor Fitzgerald set a target price of $7.0 on 05/15/2025
Full Release
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call & Webcast:
- U.S. dial-in: 201-389-0918
- International dial-in: 877-407-0890
-
Webcast:
Available via the Exagen investor relations website at
investors.exagen.com
Replay: A telephone replay will be available until Tuesday, November 18, 2025:
- U.S. replay: 201-612-7415
- International replay: 877-660-6853
- Replay passcode: 13756599
-
Webcast:
A recoding of the webcast will be available one hour after the call concludes via the Exagen investor relations website at
investors.exagen.com
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE ® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn .
Contact:
Ryan Douglas
Exagen Inc.
[email protected]
760.560.1525
